Oncology Radiopharmaceuticals Market, by Test Type (Radium-223 dichloride, Sodium iodide I-131, Lobenguane iodine-131, Lutetium-177, Yttrium-90, Fludeoxyglucose F 18, Gallium Citrate Ga 67, Technetium-99m, and Others), by Route of Administration (Oral and

Oncology Radiopharmaceuticals Market, by Test Type (Radium-223 dichloride, Sodium iodide I-131, Lobenguane iodine-131, Lutetium-177, Yttrium-90, Fludeoxyglucose F 18, Gallium Citrate Ga 67, Technetium-99m, and Others), by Route of Administration (Oral and Intravenous), by Application (Diagnosis and Treatment), by End User (Diagnostic Centres, Hospitals and Clinics, and Research Institutes), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022 - 2028

Radiopharmaceuticals are medications that contain radioactive (isotopes), which are used for the treatment or diagnose of cancer. These medications can be administered into patient’s body orally, intravenously or interstitially (inserted into a cavity in the body). Radiopharmaceuticals are inserted into the body and when it reaches the targeted area of the body, it releases radioactive agents to destroy the tumor cells. Fludeoxyglucose F 18, Gallium Citrate Ga 67, Indium In 111 Pentetreotide, Methionine C 11, Radioiodinated Iobenguane, Sodium Fluoride F 18, Technetium Tc 99m Arcitumomab, Technetium Tc 99m Nofetumomab Merpentan are the oral radiopharmaceuticals used in the diagnosis of cancer
Radiopharmaceuticals can be used to treat following cancers:
Thyroid cancer
Brain cancer
Lymphoma
Cancers that have spread to the bones

Market Dynamics

Increasing number of drug approvals from regulatory bodies is expected to drive the growth of the global oncology radiopharmaceutical market during the forecast period. For instance, in May 2021, PETNET Solutions, Inc., a Siemens Healthineers company, and Zionexa USA, a wholly-owned subsidiary of Zionexa SAS, announced that the U.S. Food and Drug Administration (FDA) approved Cerianna (fluoroestradiol F 18) injection for intravenous use. Cerianna (fluoroestradiol F 18) is the first FDA-approved F-18 PET imaging agent specifically indicated for use in patients with recurrent or metastatic breast cancer.

Increasing number of inorganic growth strategies by market players is expected to drive the growth of global oncology radiopharmaceuticals market. For instance, in June 2021, Bayer AG a pharmaceuticals and life science company announced that the company signed an agreement to acquire Noria Therapeutics Inc. and PSMA Therapeutics Inc. Noria Therapeutics Inc is a radiotherapy company developing targeted therapeutic and imaging radiopharmaceuticals. This acquisition will provide rights to Bayer to differentiate alpha radionuclide therapy based on actinium-225 and a small molecule targeting prostate-specific membrane antigen (PSMA).

Key features of the study:
This report provides an in-depth analysis of the global oncology radiopharmaceutical market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new drug launches or approval, regional outlook, and competitive strategies adopted by the leading players
It profiles leading players in the global oncology radiopharmaceutical market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans.
Key companies covered as a part of this study include Siemens Healthcare GmbH, Novartis AG, Curium, GE Healthcare, Lantheus Medical Imaging, Inc., International Isotopes, Inc., Nordion, Eckert & Zieger, Acrotech Biopharma, Blue Earth Diagnostics, Zionexa, Bayer AG, Jubilant Pharma Limited, and Cardinal Health
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global oncology radiopharmaceutical market report caters to various stakeholders in this industry including investors, suppliers, manufacturers, distributors, new entrants, and financial analysts.
Stakeholders would have ease in decision making through various strategy matrices used in analyzing the global oncology radiopharmaceutical market
Detailed Segmentation:
Global Oncology Radiopharmaceutical Market, By Type:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
Others
Global Oncology Radiopharmaceutical Market, By Route of Administration:
Oral
Intravenous
Global Oncology Radiopharmaceutical Market, By Application:
Treatment
Diagnosis
Global Oncology Radiopharmaceutical Market, By End User:
Diagnostic Centers
Hospitals and Clinics
Cancer Research Institutes
Global Oncology Radiopharmaceutical Market, By Region:
North America
By Type:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
Others
By Route of Administration:
Oral
Intravenous
By Application:
Treatment
Diagnosis
By End User:
Diagnostic Centers
Hospitals and Clinics
Cancer Research Institute
By Country:
U.S.
Canada
Latin America
By Type:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
Others
By Route of Administration:
Oral
Intravenous
By Application:
Treatment
Diagnosis
By End User:
Diagnostic Centers
Hospitals and Clinics
Cancer Research Institute
By Country:
Brazil
Mexico
Argentina
Rest of Latin America
Europe
By Type:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
Others
By Route of Administration:
Oral
Intravenous
By Application:
Treatment
Diagnosis
By End User:
Diagnostic Centers
Hospitals and Clinics
Cancer Research Institute
By Country:
U.K.
Germany
Italy
Spain
France
Russia
Rest of Europe
Asia Pacific
By Type:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
Others
By Route of Administration:
Oral
Intravenous
By Application:
Treatment
Diagnosis
By End User:
Diagnostic Centers
Hospitals and Clinics
Cancer Research Institute
By Country:
Australia
India
China
Japan
ASEAN
South Korea
Rest of Asia Pacific
Middle East
By Type:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
Others
By Route of Administration:
Oral
Intravenous
By Application:
Treatment
Diagnosis
By End User:
Diagnostic Centers
Hospitals and Clinics
Cancer Research Institute
By Country:
GCC
Israel
Rest of Middle East
Africa
By Type:
Radium-223 dichloride
Sodium iodide I-131
Lobenguane iodine-131
Lutetium-177
Yttrium-90
Fludeoxyglucose F 18
Gallium Citrate Ga 67
Technetium-99m
Others
By Route of Administration:
Oral
Intravenous
By Application:
Treatment
Diagnosis
By End User:
Diagnostic Centers
Hospitals and Clinics
Cancer Research Institute
By Country/Region:
South Africa
Central Africa
North Africa
Company Profiles
Siemens Healthcare GmbH *
Company Overview
Product Portfolio
Financial Performance
Recent Highlights
Strategies
Novartis AG
Curium
GE Healthcare
Lantheus Medical Imaging, Inc.
International Isotopes, Inc.
Nordion
Eckert & Zieger
Acrotech Biopharma
Blue Earth Diagnostics
Zionexa
Bayer AG
Jubilant Pharma Limited
Cardinal Health
“*” marked represents similar segmentation in other categories in the respective section.